This private member’s bill directs the Secretary of State to put in place regulations that end the use of animals in medical research and to require researchers to use non‑animal methods when investigating human disease or testing medicines and medical devices. It also mandates government guidance to support that transition.
The measure would reshape how early‑stage biomedical work is carried out in the UK: it aims to eliminate animal models as an accepted research route and to push funding, infrastructure and regulatory practice toward human‑relevant alternatives. That creates both compliance obligations for research institutions and an enforced market signal for developers of non‑animal technologies.
At a Glance
What It Does
The bill requires the Secretary of State to make regulations that prohibit use of animals and animal‑derived biomaterials in medical research and to require non‑animal methods in research and product testing. The regulations may create criminal offences and civil sanctions and are to be enacted by statutory instrument with parliamentary approval.
Who It Affects
Universities, contract research organisations, biotech and pharma companies conducting preclinical work, manufacturers of medical devices, and providers of animal‑derived reagents would face new legal and compliance obligations. Regulators and advisory bodies named in the bill must be consulted during rulemaking.
Why It Matters
If enacted, the law would set a clear legal mandate for replacing animal models, accelerating investment in alternatives, and changing how safety and efficacy evidence is generated before human trials. It also creates a formal role for government to direct the pace and shape of that transition.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 1 directs the Secretary of State to put in place regulations that eliminate animal use in medical research and to require non‑animal approaches for work aimed at understanding human disease or for testing medicines and medical devices intended for people. The regulations are drafted to be flexible: the bill explicitly allows them to create criminal offences for breaches and to use civil sanctions where appropriate, giving the executive a range of enforcement tools.
The bill obliges consultation with several named scientific and regulatory bodies before the regulations are laid, so rulemaking must be informed by the Animals in Science Regulation Unit, the Animals in Science Committee, the Commission on Human Medicines and the Medicines and Healthcare products Regulatory Agency, among others the Secretary of State chooses to involve. That consultation list channels technical input into the design of the prohibition and any compliance regime.Separately, the Secretary of State must publish guidance for people carrying out the covered research and testing.
The guidance must advise on non‑animal research methods and set out what government or other support exists to adopt them; the Secretary may revise guidance over time and must ensure it is published and accessible. This creates a continuing administrative duty intended to assist the affected research community during the mandated shift away from animal models.The Act is drafted to apply across England, Wales, Scotland and Northern Ireland and includes standard commencement and citation language.
Taken together, the statutory ban plus the guidance and consultation requirements are designed to move the UK from animal‑based preclinical practice toward validated human‑relevant methods, while giving ministers both the power to set enforcement rules and the obligation to provide practical support.
The Five Things You Need to Know
The bill requires regulations that take effect from 1 January 2035 to prohibit the use of animals in medical research.
The Secretary of State is the statutory actor required to make the prohibition regulations.
The regulations must ban use of live animals and animal‑derived biomaterials in the covered research.
Regulations under the Act are to be made by statutory instrument and may not be made unless a draft instrument has been laid before and approved by resolution of each House of Parliament.
The Secretary of State must issue published guidance that includes advice about non‑animal research methods and information about any government or other support to adopt them.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Power and mandatory content for prohibition regulations
Section 1 places a mandatory duty on the Secretary of State to bring forward regulations that outlaw animal use in medical research and to require non‑animal methods for human disease research and testing of human medicines and devices. It also lists the substantive elements ministers may include — notably criminal offences and civil sanctions — which gives the future regulations a choice of enforcement pathways and penalties that will shape compliance costs.
Form of regulations, parliamentary approval and consultations
The bill specifies that the regulations must be made by statutory instrument and cannot be made without draft approval by both Houses, so ministers cannot use negative procedure; the affirmative route raises political visibility and oversight. Before laying the draft, the Secretary of State must consult named advisory and regulatory bodies, tethering the delegated rulemaking to expert input from the Animals in Science Unit, the Animals in Science Committee, the Commission on Human Medicines and the MHRA.
Guidance duty and support information
Section 2 requires the Secretary of State to produce guidance aimed at the people and organisations affected by the regulations, to include practical advice on non‑animal methods and details of support available. The provision also allows the Secretary to revise guidance and requires publication, creating an ongoing executive obligation to provide technical and funding information that will affect how institutions plan transitions.
Territorial reach, commencement and short title
Section 3 confirms the bill’s application across the whole UK, stipulates that the Act comes into force on the day it receives Royal Assent, and sets the short title. While the primary operational prohibition will come later under regulations, this section fixes the Act’s territorial ambit and gives ministers immediate authority to begin the rulemaking process.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and future clinical trial participants — receive stronger incentives for research methods that are human‑relevant, which could improve translational predictivity over time.
- Animal welfare organisations — the statutory ban directly advances their objective to end animal use in medical research and provides a legal hook for advocacy and enforcement.
- Companies and labs developing non‑animal technologies (in‑vitro systems, organ‑on‑chip, computational models) — gain a clearer market signal and potential demand surge for validated alternative methods.
- Regulatory science providers and test method validators — stand to benefit from increased demand for method validation, standardisation services and training to support the mandated transition.
Who Bears the Cost
- Universities and biomedical research groups that currently rely on animal models — face retooling costs, retraining, validation studies and potential disruption to ongoing programmes.
- Pharmaceutical and device manufacturers and contract research organisations — will need to redesign preclinical packages, fund alternative‑method validation, and potentially face delays or higher costs during the transition.
- Suppliers of animal‑derived reagents and animal husbandry services — will see market contraction for those products and infrastructures.
- Regulators and government agencies (including those consulted) — must absorb rulemaking, guidance production, monitoring and possible enforcement tasks, which may require additional resources and new technical capacities.
Key Issues
The Core Tension
The central dilemma is between eliminating animal use on ethical and scientific grounds and ensuring that medicines and devices entering human testing remain safe and effective: a statutory ban advances one policy goal decisively, but it shifts the burden to regulators, industry and funders to develop, validate and accept alternative evidence streams — a process that can be resource‑intensive, technically difficult and internationally sensitive.
The bill creates a strong legal directive but leaves many implementation levers to subsequent secondary legislation and guidance. That approach concentrates decision‑making in the regulations and in ministerial guidance: the shape of prohibitions, the scope of permitted exemptions (if any), the definition of ‘‘non‑animal methods’’ for regulatory acceptance, and the level and type of sanctions will all be determined later.
That raises immediate questions about how regulators will validate alternative methods and how evidence packages for safety and efficacy will be judged in the absence of animal data.
Operationally, the 2035 target for bringing the prohibition into force (via regulations) creates a long transition window, but the bill does not specify interim milestones, transitional exemptions or funding lines for method development and validation. The consultation list ties technical expertise to the rulemaking process, but it does not guarantee that the necessary validation infrastructure (standards bodies, reference laboratories, proficiency testing) will be in place on time.
International regulatory divergence is another practical tension: manufacturers selling globally will still need to meet foreign regulators’ preclinical expectations, which could produce duplicative testing or slow market access unless equivalence is negotiated.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.